Iptakalim: A novel multi-utility potassium channel opener

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 1, 2012, Pages 12-14

  Sikka, Pranav ^a   Kapoor, Seema ^b   Bindra, V ^c   Saini, Manish ^a   Saxena, K ^a  

^a LLRM MEDICAL COLLEGE   (India)

^b Departments of Oral Pathology and Microbiology   (India)

^c IDST   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IPTAKALIM; POTASSIUM CHANNEL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; COCAINE DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW;

EID: 84859573882     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.92495     Document Type: Review

References (25)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010; 121: e46-e215.
2. Feig PU, Roy S, Cody RJ. Antihypertensive drug development: current challenges and future opportunities. J Am Soc Hypertens 2010; 4: 163-73.
3. Zhou F, Wu JY, Yao HH, Ding JH, Hu G. Iptakalim alleviates rotenoneinduced degeneration of dopaminergic neurons through inhibiting microgliamediated neuroinflammation. Neuropsychopharmacology 2007; 32: 2570-80.
4. Pan Z, Huang J, Cui W, Long C, Zhang Y, Wang H. Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol 2010; 56: 215-28.
5. Wang H, Xie WP, Wang H, Hu G. Effects of iptakalim on endothelin-1- induced pulmonary hypertension in rats. Chin J Clin Pharmacol Ther 2005; 10: 9-14.
6. Wang H, Long C, Duan Z, Shi C, Jia G, Zhang Y. A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res 2007; 73: 497-503.
7. Zhao RJ, Wang H. Chemerin/ChemR23 signaling axis is involved in the endothelial protection by KATP channel opener iptakalim. Acta Pharmacol Sin 2011; 32: 573-80.
8. Gao S, Long CL, Wang RH, Wang H. KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res 2009; 83: 444-56.
9. Neylon CB. Potassium channels and vascular proliferation. Vascul Pharmacol 2002; 38: 35-41.
10. Brevnova EE, Platoshyn O, Zhang S, Yuan JX. Overexpression of human KCNA5 increases IKV and enhances apoptosis. Am J Physiol Cell Physiol 2004; 287: C715-22.
11. Cole WC, Clement-Chomienne O. ATP-sensitive K+ channels of vascular smooth muscle cells. J Cardiovasc Electrophysiol 2003; 14: 94-103.
12. Zhu Y, Zhang S, Xie W, Li Q, Zhou Y, Wang H. Iptakalim inhibited endothelin-1-induced proliferation of human pulmonary arterial smooth muscle cells through the activation of K (ATP) channel. Vascul Pharmacol 2008; 48: 92-9.
13. Xue H, Zhang YL, Liu GS, Wang H. A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005; 315: 501-9.
14. Dunn-Meynell AA, Rawson NE, Levin BE. Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res 1998; 814: 41-54.
15. Thomzig A, Laube G, Pruss H, Veh RW. Pore-forming subunits of K-ATP channels, Kir6.1 and Kir6.2, display prominent differences in regional and cellular distribution in the rat brain. J Comp Neurol 2005; 484: 313-30.
16. Abekawa T, Ito K, Koyama T. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 261-71.
17. Sun T, Hu G, Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidineinduced hyperlocomotion, but attenuates inhibition on amphetamine- induced hyperlocomotion: Relevance to animal models of antipsychotic drugs. Eur J Pharmacol 2009; 602: 334-42.
18. Wang S, Hu LF, Zhang Y, Sun T, Sun YH, Liu SY, et al. Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats. Neuropsychopharmacology 2006; 31: 933-40.
19. Yang YJ, Wang QM, Hu LF, Sun XL, Ding JH, Hu G. Iptakalim alleviated the increase of extracellular dopamine and glutamate induced by 1-methyl-4- phenylpyridinium ion in rat striatum. Neurosci Lett 2006; 404: 187-90.
20. Sun T, Zhao C, Hu G, Li M. Iptakalim: A Potential Antipsychotic Drug with Novel Mechanisms? Eur J Pharmacol 2010; 634: 68-76.
21. Wang H, Zhang YL, Tang XC, Feng HS, and Hu G. Targeting ischemic stroke with a novel opener of ATP-sensitive potassium channels in the brain. Mol Pharmacol 2004; 66: 1160-8.
22. Wang S, Hu LF, Yang Y, Ding JH, Hu G. Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease? Neuropharmacology 2005; 48: 984-92.
23. Yang Y, Liu X, Ding JH, Sun J, Long Y, Wang F, et al. Effects of iptakalim on rotenone-induced cytotoxicity and dopamine release from PC12 cells. Neurosci Lett 2004; 366: 53-7.
24. Yang Y, Liu X, Long Y, Wang F, Ding JH, Liu SY, et al. Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats. J Neurosci Res 2005; 80: 442-9.
25. Liu Y, He HR, Ding JH, Gu B, Wang H, Hu G. Iptkalim inhibits cocaine challenge-induced enhancement of dopamine levels in nucleus accumbens and striatum of rats by up-regulating Kir6.1 and Kir6.2 mRNA expression. Acta Pharmacol Sin 2003; 24: 527-33.